|  Sign up!  

scientia

Return to Course Listing

 

 

CME: Advances in Treating Metastatic Colorectal Cancer (CRC): Optimizing Recognition and Pharmacotherapeutic Management Strategies

 


Program Description / Statement of Need:

In this online CME self-learning program:

 

Colorectal cancer (CRC) is the third-leading cause of cancer deaths in the U.S. While a majority of patients are diagnosed before their disease has metastasized, a fifth of patients have advanced disease at the time of diagnosis. Early detection and screening have been shown to significantly reduce CRC mortality, and screening is widely recommended for average-risk adults beginning at age 50 years, (as well as earlier for individuals at higher risk). Since the mid-1990s, the U.S. Preventive Services Task Force, American Cancer Society, and other groups have recommended several modalities for screening: fecal occult blood testing (FOBT), flexible sigmoidoscopy, colonoscopy, and barium enema. Recent years have seen the addition of newer screening technologies, including stool DNA, computed tomographic colonography, and capsule endoscopy.

 

Agenda

 

Faculty introduction, disclosures 

Introductory content, screening, and diagnosis [Learning Objective #1]

  • Epidemiology and prognosis, stratified by disease stage
  • Risk factors, high vs. moderate risk: family history and IBD vs. modifiable risk factors
  • ACS CRC screening recommendations and barriers to care in screening
  • Role of screening and prognostic tests
  • AJCC staging
  • The role of genetics, tumor mutations / biomarkers, and heritable syndromes
  • Patient case(s)

Treatment of CRC [Objectives #2 & 3]

  • Model for pathogenesis and cancer development in mCRC
  • Brief review of stages II & III to compare / contrast with mCRC treatment
  • Survivorship surveillance
  • mCRC: introductory case review
  • Personalizing treatment regimens
  • First-line therapies
  • Liver-limited mCRC, liver metastases
  • Evolving role of biomarkers’ roles in guiding treatment: KRAS, BRAF, others
  • Developing patient-specific plans to treating mCRC
  • Describe current and emerging therapies, including targeted mechanisms in the treatment of mCRC: angiogenesis including tyrosine inhibition, epidermal growth factor inhibition, novel metabolism inhibitors, radioactive isotopes in liver metastases, emerging biosimilars
  • Therapy after disease progression
  • Clinical literature updates
  • Barriers: Suboptimal screening and prep, awareness and best practices in patient education
  • Putting it all together: integrated, best practice
  • Patient case(s)

Summary, conclusions, and best practice recap


 

Target Audience:

Healthcare professionals including: medical oncologists, primary care physicians, pathologists, gastroenterologists, and managed care medical care directors; physicians assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and other clinicians who are involved in providing diagnostic and therapeutic services for patients with CRC.



Program Objectives:

By the end of the session the participant will be able to:

    • Describe present practice guideline recommendations with respect to colorectal cancer screening, including colonoscopy preparation, and apply them to patient cases
    • Identify the treatment modalities currently available for management of mCRC and apply them to patient cases using evidence-based medicine
    • Evaluate a treatment plan for a specific patient with mCRC to optimize safety, efficacy, and tolerability, suggesting modifications for improvement
    • Describe the challenges and barriers to care associated with treating patients with mCRC


    Accreditation:

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

     

    Credit Designation: ScientiaCME designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

     

    Pharmacists

     

    ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.  ACPE # 0574-0000-17-041-H01-P.  ACPE Accreditation effective 10/19/17, expires 10/19/19. 

    This is a Knowledge (K)-type activity.



    Release Date: October 19, 2017
    Expiration Date: October 19, 2019

    Faculty: Laleh Melstrom MD


    Faculty Disclosure and Resolution of COI:

     As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

     

    Faculty Disclosure:  Lelah Melstrom, M.D., M.S., F.A.C.S., Surgeon and Research, City of Hope Medical Center, Duarte, CA as no relevant financial disclosures.

     

    Disclosures of Educational Planners: Charles Turck, PharmD has no relevant financial disclosures.

     

    Commercial Support Disclosure: This program is supported by educational grants from AMGEN.


    Additional Courses That Are Related To This Course


    Non-Small Cell Lung Cancer (NSCLC): Highlights from the 2016 American Society for Clinical Oncology: Take-Aways, Emerging Practice Changes, and Barriers to their Implementation

    Metastatic Melanoma: Novel Approaches in Immuno- and Molecularly-Targeted Therapy, Therapeutic Updates, and Best Practices in Involving the Patient in Care

    Metastatic Melanoma: Updates from ASCO 2017

    Basal Cell Carcinoma (BCC): Therapeutic Updates, Best Practices, and the Role of Personalized Patient Care

     

    Viewing Instructions

     

    PC

    Windows 2000 or above
    Internet Explorer 5.5
    Adobe Acrobat Reader*

    MAC
    Mac OS 10.2.8
    Safari
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh

     

    *Required to view Printable PDF Version

     

    Privacy Policy

     

    Instructions:


    -Read the learning objectives and faculty disclosures above

    -Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.

    -View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.

    -Take the post-test

    -Complete the program evaluation and CME registration. A CE certificate will be emailed to you.


    Perform Pre-Test (optional)
    Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


    Download the Presentation (optional)


     

    View the online program

     

    Perform Post-Test


    Complete the Symposium Evaluation and Request CE Certificate



This program is supported by educational grants from AMGEN.

 


Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.